MENU
SLDB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Solid Biosciences (SLDB) Ownership - Who owns Solid Biosciences?

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases... Show more

Industry: #Biotechnology

Profile

Industry
Biotechnology
Address
500 Rutherford Avenue
Phone
+1 617 337-4680
Employees
121
Web
https://www.solidbio.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
932.32M
P/E Ratio
N/A
Total Cash
380.68M
Projected Growth
N/A
Total Debt
20.67M
Revenue
N/A
Risk (Beta)
2.47
Dividend Yield
N/A
Total Cash/Share
3.87
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
View a ticker or compare two or three
SLDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of novel gene therapy platform for advancing disease

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
500 Rutherford Avenue
Phone
+1 617 337-4680
Employees
121
Web
https://www.solidbio.com